Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Related Videos

Related Content

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL

January 18th 2023

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL

January 18th 2023

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL

January 18th 2023

Related Content

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Article

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Podcast

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Article

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

Podcast

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Article

Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL

January 18th 2023

Article